{
    "organizations": [],
    "uuid": "494c23ec1fff22c30fca340cc7f6acaed23e5ac0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-amgen-receives-positive-chmp-opini/brief-amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspire-study-to-kyprolis-label-idUSFWN1S70RI",
    "ord_in_thread": 0,
    "title": "BRIEF-Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 Aspire Study To Kyprolis Label",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Amgen Inc:\n* AMGEN RECEIVES POSITIVE CHMP OPINION TO ADD OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ASPIRE STUDY TO KYPROLISÂ® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T21:10:00.000+03:00",
    "crawled": "2018-05-01T19:51:07.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "amgen",
        "inc",
        "amgen",
        "receives",
        "positive",
        "chmp",
        "opinion",
        "add",
        "overall",
        "survival",
        "result",
        "phase",
        "aspire",
        "study",
        "carfilzomib",
        "label",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}